Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 17, 2012

Poll Respondents Divided on Impact of FDA Legislation on Investing Environment

  • Respondents to a recent GEN poll appear divided on how useful FDA legislation designed to speed up drug approvals, and now sailing through Congress, will be on improving the investment climate. More than one-third of respondents (37.5%) believe the measure will be “somewhat” useful, but another one-third-plus (35%) answered “not very useful.” Another 27.5% said the legislation will be “very” useful; no respondents were undecided.

    Key committees of the Senate and House of Representatives have marked up bills combining a fifth reauthorization of the Prescription Drug User Fee Act (PDUFA V) with provisions based on predecessor bills that include the Faster Access to Specialized Treatments (FAST) Act introduced in the House of Representatives, the Transforming the Regulatory Environment to Accelerate Access to Treatments (TREAT) Act introduced in the Senate, and another Senate bill, the Advancing Breakthrough Therapies for Patients Act of 2012.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »